Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.

<h4>Background</h4>SARS-CoV-2 invades human cells and leads to COVID-19 by direct associating with angiotensin converting enzyme 2 (ACE2) receptors, the level of which may be increased by treatment with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers...

Full description

Bibliographic Details
Main Authors: Nancy Xurui Huang, Qi Yuan, Fang Fang, Bryan P Yan, John E Sanderson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0280280
_version_ 1797944025527877632
author Nancy Xurui Huang
Qi Yuan
Fang Fang
Bryan P Yan
John E Sanderson
author_facet Nancy Xurui Huang
Qi Yuan
Fang Fang
Bryan P Yan
John E Sanderson
author_sort Nancy Xurui Huang
collection DOAJ
description <h4>Background</h4>SARS-CoV-2 invades human cells and leads to COVID-19 by direct associating with angiotensin converting enzyme 2 (ACE2) receptors, the level of which may be increased by treatment with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs). This meta-analysis aimed to explore the impact of ACEI/ARB treatment on the clinical outcomes of patients with COVID-19 infections among population in the East-Asia region.<h4>Methods</h4>We collected clinical data published from January 2000 to May 2022 in the English databases including PubMed, Embase, and the Cochrane Library. Two reviewers independently screened and identified studies that met the prespecified criteria. Review Manager 5.3 software was used to perform the meta-analysis.<h4>Results</h4>A total of 28 articles were included in this analysis. The results showed that patients who were prescribed with ACEI/ARB had a shorter duration of hospital stay [MD = -2.37, 95%CI (-3.59, -1.14), P = 0.000 2] and a lower mortality rate [OR = 0.61, 95% CI (0.52, 0.70), P<0.000 01] than patients who were not on ACEI/ARB. Furthermore, there was no statistically significant difference in disease severity [OR = 0.99, 95% CI (0.83, 1.17), P = 0.90] between individuals receiving ACEI/ARB or not.<h4>Conclusions</h4>This meta-analysis suggested that the use of ACEI/ARB was not associated with adverse clinical outcomes in East-Asian Covid-19 patients and a reduced mortality and shorter duration of hospital stay among East-Asian population (especially for female subjects) was found. Thus, ACEI/ARB should be continued in patients infected by Covid-19.
first_indexed 2024-04-10T20:32:06Z
format Article
id doaj.art-ba8d077d5885418fb83d25b9d51e7d1e
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-10T20:32:06Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-ba8d077d5885418fb83d25b9d51e7d1e2023-01-25T05:32:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01181e028028010.1371/journal.pone.0280280Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.Nancy Xurui HuangQi YuanFang FangBryan P YanJohn E Sanderson<h4>Background</h4>SARS-CoV-2 invades human cells and leads to COVID-19 by direct associating with angiotensin converting enzyme 2 (ACE2) receptors, the level of which may be increased by treatment with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs). This meta-analysis aimed to explore the impact of ACEI/ARB treatment on the clinical outcomes of patients with COVID-19 infections among population in the East-Asia region.<h4>Methods</h4>We collected clinical data published from January 2000 to May 2022 in the English databases including PubMed, Embase, and the Cochrane Library. Two reviewers independently screened and identified studies that met the prespecified criteria. Review Manager 5.3 software was used to perform the meta-analysis.<h4>Results</h4>A total of 28 articles were included in this analysis. The results showed that patients who were prescribed with ACEI/ARB had a shorter duration of hospital stay [MD = -2.37, 95%CI (-3.59, -1.14), P = 0.000 2] and a lower mortality rate [OR = 0.61, 95% CI (0.52, 0.70), P<0.000 01] than patients who were not on ACEI/ARB. Furthermore, there was no statistically significant difference in disease severity [OR = 0.99, 95% CI (0.83, 1.17), P = 0.90] between individuals receiving ACEI/ARB or not.<h4>Conclusions</h4>This meta-analysis suggested that the use of ACEI/ARB was not associated with adverse clinical outcomes in East-Asian Covid-19 patients and a reduced mortality and shorter duration of hospital stay among East-Asian population (especially for female subjects) was found. Thus, ACEI/ARB should be continued in patients infected by Covid-19.https://doi.org/10.1371/journal.pone.0280280
spellingShingle Nancy Xurui Huang
Qi Yuan
Fang Fang
Bryan P Yan
John E Sanderson
Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
PLoS ONE
title Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
title_full Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
title_fullStr Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
title_full_unstemmed Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
title_short Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
title_sort systematic review and meta analysis of the clinical outcomes of acei arb in east asian patients with covid 19
url https://doi.org/10.1371/journal.pone.0280280
work_keys_str_mv AT nancyxuruihuang systematicreviewandmetaanalysisoftheclinicaloutcomesofaceiarbineastasianpatientswithcovid19
AT qiyuan systematicreviewandmetaanalysisoftheclinicaloutcomesofaceiarbineastasianpatientswithcovid19
AT fangfang systematicreviewandmetaanalysisoftheclinicaloutcomesofaceiarbineastasianpatientswithcovid19
AT bryanpyan systematicreviewandmetaanalysisoftheclinicaloutcomesofaceiarbineastasianpatientswithcovid19
AT johnesanderson systematicreviewandmetaanalysisoftheclinicaloutcomesofaceiarbineastasianpatientswithcovid19